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Background: Human cytomegalovirus (HCMV) causes serious HCMV-related diseases in immunocompromised
people. Vaccination is the most effective measure to control infection with the pathogen, yet no vaccine has been
licensed till now. We performed a head-to-head comparison of the protective abilities of multiple DNA vaccines in
murine model of murine cytomegalovirus (MCMV) infection.
Methods: Five DNA vaccines were constructed. Four encoding MCMV proteins gp34 (m04), p65 (M84), DNA
helicase (M105), and immediate-early 1 protein pp89 (IE-1) , respectively, which were reported to induce CD8+ T cell
responses, were compared with the one expressing gB (M55), the neutralizing antibody target antigen, for immune
protection in BALB/c mice. Mice were immunized with these DNA vaccines 1 to 4 times via intramuscular injection
followed by electroporation, and were subsequently infected with a lethal dose (3 × LD50) of highly virulent
SG-MCMV. Specific antibodies and IFN-γ secreting splenocytes were detected by immunoblotting and ELISPOT,
respectively. Protective abilities in mice provided by the vaccines were evaluated by residual virus titers in organs,
survival rate and weight loss.
Results: These DNA vaccines, especially m04, M84 and IE-1, could effectively reduce the virus loads in salivary
glands and spleens of mice, but they couldn’t completely clear the residual virus. Survival rates of 100% in mice
after a lethal dose of MCMV infection could be reached by more than one dose of M84 vaccine or two doses of
m04 or IE-1 vaccine. Immunization with M55 or M105 DNA at four doses offered mice only 62.5% survival rate
after the lethal challenge.
Conclusions: The study demonstrated that DNA vaccines could effectively afford mice protection against infection
with a highly virulent MCMV and that the protection offered by induced CD8+ T cell immunity might be superior to
that by gB-specific antibodies. These results are valuable references for development and application of HCMV vaccines.
Keywords: Cytomegalovirus, DNA vaccine, M04 (gp34), M84 (p65), M105 (DNA helicase), IE-1 (pp89),
M55 (glycoprotein B)Background
Human cytomegalovirus (HCMV) is a common human
herpesvirus, with infection rate of 40 ~ 90% in general
population. However, it only causes clinical symptoms in
people with a not-fully-developed or compromised immune
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Each year, 0.4 ~ 0.7% of newborns have congenital HCMV
infections in the United States, of which 12.7% show some
symptoms at birth and ultimately develop hepatospleno-
megaly, thrombocytopenic purpura, microcephaly, sensori-
neural hearing loss (SNHL) and/or neurodevelopmental
delay [2,3]. No specific treatment is currently available for
HCMV infected pregnant women and infants with con-
genital or perinatal HCMV infections. Vaccination is the
most effective measure to control infection with the patho-
gen. Development of a vaccine against HCMV infectionLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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search [4], yet no vaccine has been licensed till now due to
unsatisfactory results of clinical trials on the current
HCMV vaccine candidates. Many researches are still in pre-
clinical stage except three, two with a neutralizing antibody
inducing gB subunit vaccine plus MF59 adjuvant [5,6] and
one with a bivalent DNA vaccine (TransVax™) containing
plasmids encoding gB and pp65 formulated with poloxa-
mer CRL1005 and benzalkonium chloride, which have
completed phase II clinical trials [7]. The gB/MF59 vaccine
exhibited a vaccine efficacy of 50% in CMV-seronegative
women and had the potential to decrease incident
cases of maternal and congenital CMV infection [6].
The gB/MF59 and the DNA vaccine both could limit
the periods of viraemia and consequently the need
for antiviral treatment in organ-transplant patients
[5,7]. The paper by F. Rieder and C. Steininger reviewed
these completed phase II clinical trials on HCMV
vaccines [8]. Now evaluation of ASP0113 (formerly
TransVax™) is ongoing in phase III trials (NCT01877655
at www.clinicaltrials.gov).
A suitable animal model is very useful for the study of
HCMV pathogenicity and protective immune responses
of HCMV vaccines in humans. However, strict species
specificity of CMV has restricted the possibility of estab-
lishing an animal model of HCMV infection. The MCMV
is similar to HCMV in virion structure, genome organi-
zation, gene expression, tissue tropism and latency. There-
fore, mouse model of MCMV infection has now been
widely used in exploring HCMV infection [9,10]. Similar
with HCMV, MCMV is expressed in three sequential
phases, immediate early (IE), early (E) or late (L) after
infecting host cells, which show coordinate regulation and
temporal control [11]. MCMV M123 (IE-1) is the hom-
ologous gene of HCMV UL123 (IE-1), and is expressed at
the IE phase of MCMV replication as a non-structural
protein pp89. M84 is expressed in E phase of replication
as a non-structural protein of 65 kD (p65), and its homo-
logous protein pp65 in HCMV is the main antigen for
cytotoxic T lymphocyte (CTL) response against HCMV
infection in humans [12,13]. The m04 gene is only present
in MCMV, and is expressed in E phase of virus replication
as gp34 protein and plays an important role in immune
escape of MCMV [14,15]. M105 is expressed as DNA heli-
case of MCMV, which is necessary for MCMV replication
in the host. M105 and its HCMV homolog UL105 are
highly conserved [16]. M55 gene and its HCMV counter-
part UL55 gene both encode the envelope glycoprotein B
(gB), the target antigen recognized by CMV-specific
neutralizing antibodies. As a new type of vaccine, DNA
vaccine could carry antigen-coding genes of a pathogen
and induce humoral and/or cellular immune responses
in vivo. At the same time, DNA vaccine offers a method
for selecting effective antigens. Thus we chose to deliverviral components in the form of DNA vaccine, and per-
formed a head to head comparison of five different MCMV
DNA vaccines for their capacities in inducing immune
responses and providing protection against MCMV
infections.
Results
Survival rates of mice against a lethal SG-MCMV infection
To evaluate the protection provide by the five DNA vac-
cines, 420 female, 6 ~ 8 week old BALB/c mice were ran-
domly divided into 21 groups, 20 mice each. One group
was the unimmunized control. The other 20 groups were
immunized with m04, M84, M105, IE-1 and M55 DNA
vaccine at a dosage of 100 μg for 1 ~ 4 times, respectively,
via intramuscular injection plus electroporation. The im-
munization interval was two weeks for multiple doses.
Fourteen days after the final immunization, mice were
infected via intraperitoneal injection with a lethal dose
(3 × LD50) of SG-MCMV. After infection of mice, the sur-
vival rate, body weight change and residue virus loads in
organs were monitored.
The survival rates of mice were recorded within
21 days post-infection (d.p.i.). As shown in Table 1, mice
in control group were unimmunized and all died within
7 days after a lethal virus challenge. Compared with the
control, mice immunized with all the plasmids except
M55 DNA obtained protection against infection even at
one dose of injection, with the survival rates of 81.3%,
75%, 31.3% and 68.8% for m04, M84, M105 and IE-1
groups, respectively. M55 could only provide partial
protection (56.3%) for mice at more than 2 doses of
injection. Among the four DNA vaccines, i.e. m04, M84,
M105 and IE-1,100% survival rate against a lethal MCMV
infection was achieved in mice with more than one dose
of M84 DNA or more than two doses of either m04 or
IE-1 DNA, whereas protective ability provided by M105
was overall poor with multiple immunizations, almost the
same as that by M55. The results demonstrated that
immunization with m04, M84 or IE-1 DNA vaccine could
achieve 100% survival rate against a lethal MCMV infec-
tion. Meanwhile, M105, the same as M55 DNA, only
provided partial protection.
Body weight changes of mice after the lethal SG-MCMV
challenge
Body weight changes of mice were also recorded within
21 days post-infection. As shown in Figure 1, within the
first few days after the challenge, i.e., the acute phase of
infection, all mice had drastic weight loss, but significant
difference was present in some of the m04, M84 and IE-1
groups compared with the control group and the M55
group. In the control group, the maximal weight loss
reached 23% and mice all died within 7 days. The weight
losses of all the immunized groups were lower than that
Table 1 Survival rates of mice after lethal virus challenge§
Vaccine Survival rates (No. of survivors/No. tested)
One dose Two doses Three doses Four doses
M04 13/16 (81.3%)a,b 15/16 (93.8%)a,b 16/16 (100%)a,b 16/16 (100%)a,b
M84 12/16 (75%)a,b 16/16 (100%)a,b 16/16 (100%)a,b 16/16 (100%)a,b
M105 5/16 (31.3%)a 6/16 (37.5%)a 8/16 (50%)a 10/16 (62.5%)a
IE-1 11/16 (68.8%)a,b 14/16 (87.5%)a,b 16/16 (100%)a,b 16/16 (100%)a,b
M55 0/16 (0%) 0/16 (0%) 9/16 (56.3%)a 10/16 (62.5%)a
Control 0/16(0%)
§Mice were immunized 1 ~ 4 times, at an interval of 2 weeks, with 100 μg plasmid DNAs. Two weeks after the final immunization, mice were challenged with a
lethal dose (3 × LD50) of SG-MCMV. The survival rates of mice were determined 21 days postinfection.
aSignificant difference compared with control animals, P < 0.05.
bSignificant difference compared with the M55 group at the same immunization frequency.
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offered by immunization with these DNA vaccines. The
maximal weight losses were on day 3–5 p.i., and after-
wards mice gradually gained weights. Weight loss moder-
ated along with the increase of the immunization frequencyFigure 1 Bodyweight changes after virus challenge. Mice were immun
DNAs encoding M04, M84, M105, IE-1and M55, respectively. Two weeks aft
(3 × LD50) of MCMV and the body weights were measured within 3 weeks
a. Significant difference compared with control group (P < 0.05). b. Significaof a DNA vaccine. At the same immunization frequency,
the maximal weight losses in m04, M84 and IE-1 groups
were lower than those in M55 and M105 groups. By day
21 p.i., all surviving mice had recovered their body
weight to pre-challenge levels.ized 1 to 4 times (A-D) at an interval of 2 weeks, with 100 μg plasmid
er the final immunization, mice were challenged with a lethal dose
after the challenge. Data points represent mean ± SD of each group.
nt difference compared with M55 group (P < 0.05).
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In the process of infection with SG-MCMV, the spleen
is a key affected organ, in which the virus load in the
infected mice was reported to peak on 5 d.p.i. [17], and
salivary gland is another important organ for virus repli-
cation, latency and dissemination. We harvested spleens
of 4 mice from each group on 5 d.p.i. and salivary glands
of another 4 mice from the surviving mice of each group
on 21 d.p.i.. The samples were homogenized and analyzed
for virus titration by plaque assay on 3T3 cells. The results
are shown in Table 2.
On day 5 after virus infection, the virus titer of spleen
detected in the control group was 105.1 PFU/ml. The
values in all the immunized mice were significantly
lower than that in the control group. In mice immunized
with IE-1, the virus loads of spleen declined as the
immunization frequency increased and the lowest value
was 102.4 PFU/ml at 4 doses. In addition, with 4 doses of
injection, the IE-1 group had a significant decrease com-
pared with other groups; the M84 and m04 groups had
significantly lower virus titers compared with the M55
and M105 groups. There was no significant difference
between the m04 and M84 groups, as well as between
M55 and M105 groups.
As for the virus titers in salivary glands on 21 d.p.i.,
there were no detection data for the control and M55
groups at one and two doses, as no mice survived. The
highest virus titer in salivary glands was 104.2 PFU/ml
when mice were immunized thrice with M55. Compared
with the one-dose immunization, the four-dose immuni-
zation significantly reduced the virus loads in the salivary
glands of mice. In addition, with 4 doses of injection, the
M84, m04 and IE-1groups were significantly lower thanTable 2 Virus titers in the spleen and salivary glands of mice
Vaccine Spleen virus titers (Log10PFU/ml)
One dose Two doses Three doses Four doses
M04 3.9 ± 1.6a 3.5 ± 0.2a,b,e 3.6 ± 0.2a 3.2 ± 0.1a,b,c,d,
M84 3.6 ± 0.2a 3.4 ± 0.0a,e 3.5 ± 0.1a,e 3.3 ± 0.1a,b,e,
M105 3.8 ± 0.2a 3.8 ± 0.1a 3.8 ± 0.1a 3.6 ± 0.5a
IE-1 3.6 ± 0.1a 3.2 ± 0.4a,b,e 2.9 ± 0.2a,b,e 2.4 ± 0.3a,b,c,d,e
M55 3.8 ± 0.1a 3.7 ± 0.0a 3.7 ± 0.1a,b,c 3.5 ± 0.0c,d,e
Control 5.1 ± 0.1
§Mice were immunized 1 ~ 4 times, at an interval of 2 weeks, with 100 μg plasmid D
lethal dose (3 × LD50) of MCMV. Spleen virus titers 5 d.p.i. and salivary gland virus t
each group.
aSignificant difference compared with the control animals, p < 0.05.
bSignificant difference compared with the same DNA vaccine at one dose, p < 0.05
cSignificant difference compared with the same DNA vaccine at 2 doses, p < 0.05.
dSignificant difference compared with the same DNA vaccine at 3 doses, p < 0.05.
eSignificant difference compared with the M55 group at the same immunization fre
fSignificant difference compared with the IE-1 group at 4 doses, p < 0.05.
gSignificant difference compared with the M105 group at 4 doses, p < 0.05.
hSignificant difference compared with the m04 group at 4 doses, p < 0.05.
iSignificant difference compared with the M84 group at 4 doses, p < 0.05.
jNot detected, due to death of the mice.the M55 group, but there was no significant difference
between the M105 and M55 groups.
The above results demonstrated that these DNA
vaccines, especially m04, M84 and IE-1, could effectively
reduce the virus loads in organs of mice. However, they
were still weak in completely clearing the residual virus.
Humoral immune response of mice to DNA vaccines
Sera samples were collected from 4 mice of each group
by tail bleeding 13 days after the last immunization. The
specific IgG antibodies to DNA vaccines in sera of mice
were analyzed by immunoblotting. The results are shown
in Figure 2. All the plasmids could not induce a detectable
level of antibody when they were injected only once.
When they were immunized twice, all the specific anti-
body levels were raised except that to M105 antigen. The
antibody titers increased along with the increase of the
immunization frequency.
Cellular immune responses of mice to MCMV DNA vaccines
The cellular immune responses were detected by ELISPOT
assay in mice immunized four times with m04, M84,
M105 and IE-1 DNAs. The plasmid M55 was not involved
in this experiment as the H-2d restricted epitope for gB
has not been reported anywhere. Additional twenty female
mice, 6 ~ 8 weeks old, were equally grouped into 5 groups,
4 mice each. One group was used as control and remained
unimmunized. The rest 4 groups were immunized four
times with m04, M84, M105 and IE-1 DNAs at a dosage
of 100 μg, respectively, followed by electroporation. Two
weeks after the last immunization, the splenocytes were
separated from the mice, diluted appropriately, and stimu-
lated by addition of the corresponding epitope peptide.after lethal challenge§
Salivary gland virus titers (Log10PFU/ml)
One dose Two doses Three doses Four doses
e,g 3.7 ± 0.1 3.7 ± 0.2 3.7 ± 0.2e 3.3 ± 0.2b,c,d,e,g
g 3.5 ± 0.2 3.3 ± 0.2b 3.2 ± 0.2b,e 2.9 ± 0.1b,c,d,e,f,g,h
4.1 ± 0.1 3.9 ± 0.2b 3.9 ± 0.2b 3.8 ± 0.4b
,g,h 3.9 ± 0.1 3.7 ± 0.1 3.7 ± 0.1e 3.2 ± 0.2b,c,d,e,g
N.D.j N.D.j 4.2 ± 0.1 3.9 ± 0.2d
N.D.j
NAs. Two weeks after the final immunization, mice were challenged with a
iters 3 weeks p.i. were measured. Values represent mean ± SD of 4 mice from
quency, p < 0.05.
Figure 2 Detection of antibody responses by immunoblotting. Mice were immunized 1 ~ 4 times, at an interval of 2 weeks, with 100 μg
plasmid DNAs. The serum samples were collected 13 days after the last immunization for titration of antibody responses by immunoblotting.
Results are expressed as mean ± SD of 4 mice from each group. a. Not detectable.
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assays.
The ELISPOT results are shown in Figure 3 and demon-
strated that m04-, M84-, M105- and IE-1-specific IFN-γ se-
creting splenocytes could be detected in the corresponding
DNA immunization groups. The spot numbers were largely
consistent with protection. For every 5 × 105 splenocytes,
the number of induced IFN-γ secreting splenocytes was
highest in the IE-1 DNA vaccine group, reaching 779 ± 49.0
spots (range, 703 to 831). The m04 group came next
and reached 662 ± 114.2 spots (range, 474 to 681). The
M84 group had 595 ± 78.6 spots. The M105 group, which
showed relatively weak protection, had 472 ± 190 spots. In
contrast, only less than 10 spots were detected when theFigure 3 Detection of IFN-γ secreting splenocytes by ELISPOT assays.
control mice were stimulated with 4 μg/ml of the corresponding peptide
a. Significant difference compared with control group (P < 0.05). b. Significepitope peptides were used to stimulate splenocytes from
the unimmunized mice. The IFN-γ secreting spleno-
cytes in each of the immunized groups were significantly
(p < 0.05) higher than those in the control group. Among
the four immunized groups, the IE-1 group had a signifi-
cantly higher number of spot than the M105, and there
was no significant difference between other groups.
Discussion
Because of strict species specificity of CMV, it is hard to
establish an animal model of HCMV infection. The mouse
model of MCMV infection has therefore been generally
used in development of HCMV vaccines. As we know,
CMV-specific humoral immunity and CMI both playThe splenocytes from m04-, M84-, M105- and IE-1- vaccinated mice and
, respectively. Data shown represent the mean ± SD of each group.
ant difference compared with M105 group (P < 0.05).
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antibodies could effectively decrease primary infection of
CMV, and also block CMV infection of the fetus [18-20].
However, replicating or latent viruses in the host are
cleared mainly by CMI. In transplant recipients with
impaired CMI, HCMV specific T-lymphocyte responses
and HCMV diseases had inverse correlation [16]. CD8+ T
cells responded to a large panel of HCMV antigens ex-
pressing during different phases of replication and played
an important role in the overall pathogenesis of HCMV
associated diseases [21]. DNA vaccine offers a method for
selecting effective antigens. Among the five MCMV DNA
plasmids constructed in our present study, M55 DNA that
codes for the surface glycoprotein gB induces the neutral-
izing antibody, while the rest four have been reported to
induce CD8+ T cell responses [16,22,23]. M55 DNA could
only provide partial protection even at four doses. The
protections for mice offered by m04, M84 or IE-1 plasmid
were proved to be superior to that by M55. Immunization
with m04, M84 or IE-1 plasmid at more than one or two
doses could provide 100% survival rate for mice against
the lethal challenge. A series of MCMV DNA vaccines,
including M105, IE-1, M84 and m04, had been evaluated
for their protective abilities in separate papers [16,22-24],
and proved that they could afford mice some degree of
resistance against a sublethal SG-MCMV infection. How-
ever, in the present paper, we made a head-to-head
comparison of these MCMV DNA vaccines in the
same animal model and we think that challenge of mice
with a lethal dose of the virus would gain a more direct
and intuitional result than a sublethal challenge.
Besides the survival rate, the residue virus titers in
organs and the body weight changes of mice are also
very important factors in assessing the CMV vaccines.
MCMV infects mice via i.p. and acutely replicates in
multiple organs, including spleen, liver, lung, and salivary
glands. Virus peaks in spleen and liver around 5 d.p.i.,
drops to the limit of detection by 9 d.p.i. [25]. Meanwhile,
the spleen is the most important organ for T cell res-
ponses. We tested the virus titers of spleen in mice 5 d.p.i.
(Table 2). Compared with the control, all the vaccinated
groups showed the significantly lower virus titers of
spleen. The lowest titer appeared in the IE-1 group at 4
doses, and the titers in the m04 and M84 groups were
similar, a little higher than that in the IE-1 group. The
highest virus titer in spleens of mice after 4 doses of
immunization was the M105 group. This result corre-
sponded with that of the IFN-γ secreting splenocytes by
ELISPOTassay, in which IE-1 group had the highest num-
ber of IFN-secreting splenocytes (Figure 3). In the study
performed by Ye et al. [16,23,24], immunization of IE-1
plasmid also showed a relatively lower virus titer of spleen.
The reason might partly lie in the immunodominance
status of the antigen epitopes. In BALB/c mice, the H-2drestricted epitope (168-YPHFMPTNL-179) in the IE-1
protein is immunodominant [26] and those in the M84
and m04 proteins are subdominant, whereas in the M105
protein is intermediate [27]. Even so, studies by both
Spector group [16,22,23] and Holtappels group [28] had
come to a conclusion that, in BALB/c mice, the protective
potential of an antigen was independent of the immu-
nodominance status of its epitope [27]. Apart from the
spleens of mice, we also tested the salivary glands, which
are the main organ for CMV replication and latency [25],
for their virus titers. The residue virus loads of salivary
glands in the m04, M84 and IE-1 groups at 21d.p.i. were
all lower or significantly lower than those in the M55 and
M105 groups at the same immunization dose (Table 2). In
addition, the body weight of mice varied obviously and
accordingly during the first days after the lethal dose
infection (Figure 1). The mice lost less weight when a
plasmid provided better protection. Thus the survival rate,
organ virus titers and body weight changes could be con-
sidered together to evaluate the protective abilities of the
CMV vaccines in such a murine model of lethal-dose virus
infection.
Administration of the gB gene by homologous DNA
prime-boost may not be the most efficient delivery
system to develop neutralizing antibodies, yet the gB sub-
unit vaccine adjuvanted with MF59 only exhibited a
vaccine efficacy of 50% in CMV-seronegative women [6].
Therefore, in this study, we explored the importance of
the cellular immune responses against CMV infection.
We compared the protective potential of DNA vaccines
expressing a single MCMV antigen and demonstrated that
the antigens such as M84, IE-1 and m04, which are the
specific CD8+ T cell response inducer, protected mice with
100% survival rate and with obviously reduced virus loads
in organs. However, they were still weak in completely
clearing the residual virus. One reason for this may lie in
the biological nature of latent infection of CMV, and
another may be that only a single antigen was involved in
the immune responses. A study by Elkington et al. demon-
strated that in healthy immune individuals, CD8+ T cell
responses were directed towards multiple antigens (pp65,
pp50, pp28, pp150, IE-1, US2, US3, US6, US11, UL16,
UL18, gB, and gH), which may contribute to controlling
HCMV replication, and that more than 40% of the T-cell
reactivity was directed towards antigens other than pp65
and IE-1 [21]. Thus, a multi-component vaccine should be
developed in order to provide a more satisfied protection
against CMV infection. These studies are currently in
progress.
Conclusions
The results presented in this study demonstrated that
the m04, M84 or IE-1 DNA provided more effective
protection than M55 or M105 DNA for mice against a
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offered by induced CD8+ T cell immunity might be
superior to that by gB-specific antibodies. These results
are valuable references for development and application
of HCMV vaccines.
Methods
Mice, cell, and virus
Specific-pathogen-free (SPF) female BALB/c mice (H-2d),
aged 6–8 weeks, were purchased from the Center for
Disease Control and Prevention in Hubei Province, China,
and were maintained in SPF conditions prior to infection.
MCMV Smith strain was propagated in NIH 3T3 cells
(ATCC CRL 1658). The virus obtained from the cell
culture was referred to as TC-MCMV (tissue culture-
derived MCMV). TC-MCMV was propagated and puri-
fied by ultracentrifugation as described by Brune et al. [29].
The virus, which was in vivo passaged for virulence en-
hancement and isolated from salivary glands of the infected
mice, was referred to as SG-MCMV (salivary gland-derived
MCMV). The high-virulence SG-MCMV stock was pre-
pared through 14 times of in vivo passages and was used in
challenge experiments. Challenge was performed with
3× LD50 virus stock.
Plasmid DNAs and peptide
Plasmids pcDNA3.1/m04, pcDNA3.1/M84, pcDNA3.1/
M105, pcDNA3.1/IE-1 and pcDNA3.1/M55 were con-
structed by cloning the PCR products of m04, M84,
M105, IE-1and M55 gene from the MCMV smith strain
into the plasmid expression vector pcDNA3.1/myc-His
B (Invitrogen, CA), which encoded gp34, p65, DNA heli-
case, pp89 and glycoprotein B (gB) proteins, respectively.
PCR amplifications for m04, M84, M105 and M55 genes
were carried out using the following paired sense and
antisense primers: 5′AGaagcttATGTCTCTCGTATGTC
GGC3′ (containing Hind III site) and 5′GCctcgagGGTT
AGTTACTCTTAAGCGGT3′ (containing Xho I site)
for m04, 5′GCaagcttCATGTCGGTCAACGTTTACT3′
(containing Hind III site) and 5′GCtctagaGGCTCTGT
CTGTTTGTCTATG3′ (containing Xba I site) for M84,
5′GCgaattcGTTGATCATGGAGAAGAG3′ (containing
EcoR I site) and 5′GCtctagaGTCAGAAAACCAGAGT
G3′ (containing Xba I site) for M105, 5′GTaagcttGATC
GCTGAACAACGCTC3′ (containing Hind III site) and
5′GAggatccTCCTCGCAGCGTCTCCAAT3′ (containing
BamH I site) for M55. As for IE-1, its ORF has a four-
exon structure, in which three exons encoded pp89
protein [11]. We had to construct the continuous IE-1
gene by overlap-PCR with the three pairs of primers:
5′TAggatccGAGATGGAGCCCGCCGCAC3′ (containing
BamH I site) as IE-1 sense, 5′GGCGACATGAGCTGG
CACCTTGTCTGATGGGTAGAC3′ as Exon 2 antisense,
5′GTGCCAGCTCATGTCGCC3′ as Exon 3 sense, 5′ACAACAGAACGCTCCTCACTGCAGCATGCTTGA
TGG3′ as Exon 3 antisense, 5′GAGGAGCGTTCTGT
TGTC3′ as Exon 4 sense, and 5′CGgaattcGGGCTTGTG
GATTCACTTCT3′ (containing EcoR I site) as IE-1 anti-
sense. All the plasmids were propagated in E. coli
XL1-blue bacteria and purified using NucleoBond Xtra
Maxi purification kits (Macherey-Nagel, Germany).
As the H-2d restricted epitope for gB has not been
reported anywhere thus far, we only obtained epitope
peptides of the other four MCMV proteins. The peptide
243-YGPSLYRRF-251 for gp34 protein [30], 297-AYAGL
FTPL-305 for p65 protein [31], 207-TYWPVVSDI-215 for
DNA helicase [28], and 168-YPHFMPTNL-176 for pp89
protein [13] were synthesized by Shanghai Sangon
Biological Engineering Technology & Services Co., Ltd.,
and were used for IFN-γ ELISPOT assay.
Immunization
In vivo electroporation was carried out according to the
method described by Aihara and Miyazaki [32]. Mice
were immunized with plasmid DNA dissolved in 100 μl
of Tris-EDTA buffer at a dosage of 100 μg by injection
into the left and right quadriceps muscles, 50 μg each.
After the injection, a pair of electrode needles with
5 mm apart was inserted into the muscle to cover the
DNA injection sites and electric pulses were delivered
using an electric pulse generator (Electro Square Porator
T830 M; BTX, San Diego, CA). Three pulses of 100 V
each, followed by three pulses of the opposite polarity,
were delivered to each injection site at a rate of one
pulse per second. Each pulse lasted for 50 ms. The non-
immunized mice were set up as controls. Mice were
immunized 1 ~ 4 times, at an interval of 2 weeks.
Specific antibody assay
Serum samples of mice were collected 13 days after each
immunization and stored at −20°C. Titers of IgG Abs
against the respective viral proteins were measured by
using immunoblotting as previously described [33]. Con-
fluent 3T3 cells were infected with MCMV (m.o.i = 1)
for 1.5 hours at 37°C. Unadsorbed virions were removed
and infection medium was added. Cells were collected
18 hours and three days postinfection, respectively, and
then lysed. Cell lysates were separated using SDS-PAGE
(10% gel), blotted onto nitrocellulose membranes. The
membranes were blocked with the non-fat milk, dried,
and cut into longitudinal slips of 2 mm width. Serial
twofold dilutions of sera from each group of immunized
mice were prepared and each diluted serum sample was
used to incubate each membrane slip. Antibody binding
was detected using HRP-labeled goat anti-mouse IgG
(a gift from Dr. Rushi Liu) and HRP-DAB detection
kit (Sangon, China). The highest serum dilution, giving a
positive staining of slip at the site corresponding to the
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IFN-γ ELISPOT assay
Fourteen days after the 4th immunization, four mice in
each group (including M04, M84, M105, and IE-1 DNA
groups as well as the control) were euthanized for isolat-
ing spleen cells. Secretion of IFN-γ was detected by
ELISPOT using precoat ELISPOT kit (DAKEWEI, China).
According to the instruction manual, 96-well PVDF plates
(Millipore, Bedford, MA) were coated with 100 μl of
10 μg/ml rat anti-mouse IFN-γ Ab in PBS and incubated
at 4°C overnight. Next, 5 × 105 lymphocytes isolated from
the spleen cells were added to the wells in triplicate, stim-
ulated with 4 μg /ml of the corresponding synthesized
peptide, and incubated at 37°C for 20 h. The lymphocytes
were then removed, and 100 μl of biotinylated anti-mouse
IFN-γ Ab was added to each well and incubated at 37°C
for 1 h. Subsequently, 100 μl of properly diluted Streptavi-
din-HRP conjugate solution was added and incubated at
room temperature for 1 h. Finally, the plates were treated
with 100 μl of AEC substrate solution and incubated at
room temperature for 25 min in the dark. The reaction
was stopped by washing with demineralized water. The
plates were air-dried at room temperature and read using
an ELISPOT reader (Bioreader 4000; Bio-sys, Germany).
Medium backgrounds were consistently <10 spots per
5 × 105 splenocytes.
Infection
Fourteen days after the last immunization, mice were
challenged with a lethal dose (3 × LD50, 200 μl/mouse)
of the high-virulence SG-MCMV by i.p. injection. Body
weights and survival rates of mice were recorded within
21 days post-infection.
Virus titrations
Five days after the virus challenge, four mice from each
group were sacrificed and the spleens were taken asep-
tically for titration of spleen residual virus. On day 21
post-challenge, another 4 mice were taken randomly from
the remaining mice for aseptic collection of salivary glands
to determine the viral load. Spleens and salivary glands
were homogenized in 1:10 (w/v) volume with minimal
essential media (MEM) containing 2% calf serum. The
homogenized fluids were centrifuged and the supernatants
were stored in aliquots at −80°C.
Viral loads were determined using a plaque forming unit
assay. Briefly, organ homogenates were 10-fold serially
diluted and 100 μl of each dilution was used to infect 3T3
cells cultured in 48-well plates. Infections were performed
in triplicate. After 1 hour of absorption, supernatant was
sucked away and to each well was added 0.5 ml viscous
medium. After incubation for 4 days, viral plaques werecounted and the viral PFU per milliliter were calculated.
The virus titer in each experimental group was presented
as the mean of mice samples in that group ± SD.
Statistics
In this study, the experiments were repeated 3 times.
The survival rates of the mice in the test and control
groups were compared by using Fisher’s exact test. Body
weight changes between the groups were compared by
Student’s t-test. Other results between the groups were
compared by ANOVA analysis. If P-value is less than
0.05, the difference was considered significant.
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